TO ASSESS THE INCIDENCE AND SEVERITY OF COVID 19 INFECTION IN PATIENTS ALREADY ON HEPATITIS C TREATMENT

AZK CHACHAR; SR QURESHI; AH ALVI; M SOHAIB; S ALI; M ULFAT

doi:10.54112/bcsrj.v2023i1.554

Authors

AZK CHACHAR Department of Medicine, Fatima Memorial Hospital College of Medicine & Dentistry, Lahore, Pakistan
SR QURESHI Department of Gastroenterology, Fatima Memorial Hospital College of Medicine & Dentistry, Lahore, Pakistan
AH ALVI Department of Gastroenterology, Fatima Memorial Hospital, Lahore, Pakistan
M SOHAIB Department of Gastroenterology, Fatima Memorial Hospital College of Medicine & Dentistry, Lahore, Pakistan
S ALI Division of Infectious diseases, Wayne state University, Datroit, Michigan, USA.
M ULFAT Department of Medicine, Fatima Memorial Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.554

Keywords:

COVID-19, Hepatitis C, Sofosbuvir

Abstract

The COVID-19 pandemic has caused a significant impact worldwide, affecting almost every continent and every nation and causing economic challenges. Even patients who were undergoing antiviral therapy for chronic hepatitis were not spared from the deadly virus. The objective of this observational cross-sectional study was to evaluate the incidence of COVID-19 in patients already undergoing HCV treatment and to assess the severity and recovery of the disease in these patients. The study was conducted in the Department of Medicine and Gastroenterology at Fatima Memorial Hospital in Lahore and was approved by the ethical committee. The study lasted six months, and the sampling technique used was continuous non-probability sampling. The sample size was 100. The results showed that Sofosbuvir and Velpatasvir were prescribed to 91.4% of subjects, while 8.6% were taking triple therapy, including Ribavirin, Sofosbuvir, and Velpatasvir. The antiviral therapy (AVT) course lasted for three months for 95% of participants, while 5% took AVT for six months. Only 7.4% of the participants underwent COVID-19 testing; of those, 3.7% had positive results. 14.8% of participants had received the COVID-19 vaccine, and 4.9% had been in contact with someone who had tested positive for COVID-19. During the AVT period, 11.1% of participants had a history of fever, 80% had symptoms lasting for less than one week, and 20% had symptoms. These findings suggest that antiviral treatment may have a protective and preventive role in COVID-19 infection. However, further studies with a larger population will be required to strengthen these observations.

Downloads

Download data is not yet available.

References

Buonaguro, L., Tagliamonte, M., Tornesello, M. L., and Buonaguro, F. M. (2020). SARS-CoV-2 RNA polymerase as target for antiviral therapy. Journal of Translational Medicine 18, 1-8.

Dustin, L. B., Bartolini, B., Capobianchi, M. R., and Pistello, M. (2016). Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clinical microbiology and infection 22, 826-832.

Elfiky, A. A. (2020). Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life sciences 248, 117477.

Jácome, R., Campillo-Balderas, J. A., Ponce de León, S., Becerra, A., and Lazcano, A. (2020). Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Scientific Reports 10, 9294.

Messina, V., Nevola, R., Izzi, A., De Lucia Sposito, P., Marrone, A., Rega, R., Fusco, R., Lumino, P., Rinaldi, L., and Gaglione, P. (2022). Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. Scientific Reports 12, 5771.

Sadeghi, A., Ali Asgari, A., Norouzi, A., Kheiri, Z., Anushirvani, A., Montazeri, M., Hosamirudsai, H., Afhami, S., Akbarpour, E., and Aliannejad, R. (2020). Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. Journal of Antimicrobial Chemotherapy 75, 3379-3385.

Sayad, B., Khodarahmi, R., Najafi, F., Miladi, R., Mohseni Afshar, Z., Mansouri, F., Rahimi, Z., Shirvani, M., Salimi, M., and Vaziri, S. (2021). Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy 76, 2158-2167.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., and Lu, R. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine 382, 727-733.

Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S., and Yuen, K.-Y. (2016). Coronaviruses—drug discovery and therapeutic options. Nature reviews Drug discovery 15, 327-347.